PTH1R
Parathyroid hormone/parathyroid hormone-related peptide receptor
As of the edition of 20 October 2026, PTH1R (parathyroid hormone/parathyroid hormone-related peptide receptor, UniProt Q03431) has 6 drugs tested at it and 15 companies on the list, 1 on route A and 9 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q03431
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 54
- Disease areas
- Bones, joints and muscles; Nutrition and metabolism; Hormones; Injuries; Skin and connective tissue; Blood and lymph; Nervous system; Pregnancy and women's health
- Registered trials of its drugs
- 173
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Stopped | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Teriparatide | Marketed | Phase 4 | none listed |
| Parathyroid hormone | Marketed | Phase 4 | Ends 2027 |
| Abaloparatide | Marketed | Phase 4 | none listed |
| Palopegteriparatide | Marketed | Phase 3 | Ends 2037 |
| Teriparatide acetate | Marketed | Phase 2 | none listed |
| PCO-371 | Stopped | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 9 |
| Engaged | 1 |
| Undetermined | 4 |
| Total on the list | 15 |
| Company | Route |
|---|---|
| Takeda | Route B |
| Radius Health | Route B |
| Eli Lilly | Route B |
The other 12 companies at PTH1R
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at PTH1R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.